The HSA-binding domain serves to extend serum half-life and does not trigger T-cell engagement or killing; CLN-978 mediates cytotoxicity only by bridging CD19 on B cells with CD3 on T cells, leading to T cell–mediated lysis of CD19+ cells, not HSA-expressing cells.